Enterprise Value
-7.816M
Cash
77.69M
Avg Qtr Burn
N/A
Short % of Float
3.88%
Insider Ownership
18.94%
Institutional Own.
27.24%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tebipenem HBr (previously SPR994): oral carbapenem Details Bacterial infection, Urinary tract infection | Phase 3 Initiation | |
SPR206 Details Bacterial infection, Lung disease | Phase 2 Initiation | |
SPR720 Details Bacterial infection, Lung disease | Phase 2a Data readout |